- Home
- ZDAI vs REVB Comparison
ZDAI vs REVB Comparison
Compare ZDAI & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZDAI | REVB |
|---|---|---|
| Founded | 2022 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.1M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZDAI | REVB |
|---|---|---|
| Price | $0.38 | $1.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 683.4K | ★ 1.8M |
| Earning Date | 02-24-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,141,479.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $1.41 |
| 52 Week High | $1.10 | $54.48 |
Technical Indicators
Market Signals| Indicator | ZDAI | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 55.20 |
| Support Level | $0.31 | $1.43 |
| Resistance Level | $0.75 | $1.63 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 5.84 | 55.14 |
Price Performance
Historical ComparisonAbout ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).